KAY CHRISTINA 4
4 · INTEGRATED BIOPHARMA INC · Filed Sep 21, 2023
Insider Transaction Report
Form 4
KAY CHRISTINA
DirectorExecutive Vice President
Transactions
- Award
Common Stock
2023-05-25$0.40/sh+3,410,512$1,364,205→ 3,410,512 total(indirect: As Co-Executor of the Estate of E Gerald Kay) - Award
Common Stock
2023-09-20$0.09/sh+50,000$4,500→ 1,273,467 total - Award
Stock Option (right to buy)
2023-05-25+66,667→ 66,667 total(indirect: As Co-Executor of the Estate of E Gerald Kay)Exercise: $0.72From: 2021-11-04Exp: 2024-03-20→ Common Stock (66,667 underlying) - Award
Stock Option (right to buy)
2023-05-25+150,000→ 150,000 total(indirect: As Co-Executor of the Estate of E Gerald Kay)Exercise: $0.23From: 2019-05-24Exp: 2024-03-20→ Common Stock (150,000 underlying) - Award
Stock Option (right to buy)
2023-05-25+21,667→ 21,667 total(indirect: As Co-Executor of the Estate of E Gerald Kay)Exercise: $1.04From: 2022-11-03Exp: 2024-03-20→ Common Stock (21,667 underlying) - Disposition to Issuer
Stock Option (right to buy)
2023-09-20−50,000→ 200,000 totalExercise: $0.09From: 2015-06-02Exp: 2025-06-02→ Common Stock (50,000 underlying)
Footnotes (5)
- [F1]Date Ms. Kay was appointed Co-Executor of the Estate of E Gerald Kay.
- [F2]Closing price of the Issuer's Common Stock on March 20, 2023, date of transfer into the Estate of E Gerald Kay.
- [F3]50,000 common stock shares acquired upon exercise of stock option grant dated June 2, 2015.
- [F4]25,000 vested on May 24, 2019 and in 41,667 vested each May 24, 2020 and 2021 and 41,666 vested on May 24, 2022.
- [F5]33,334 vested on November 4, 2021, the one year anniversary of the grant date and 33,333 vested on November 4, 2022, the second year anniversary of the grant date.